KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Change in Account Payables: 2016-2024

Historic Change in Account Payables for Pacira BioSciences (PCRX) over the last 9 years, with Dec 2024 value amounting to $3.1 million.

  • Pacira BioSciences' Change in Account Payables fell 1985.87% to -$12.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.0 million, marking a year-over-year decrease of 228.11%. This contributed to the annual value of $3.1 million for FY2024, which is 236.68% up from last year.
  • According to the latest figures from FY2024, Pacira BioSciences' Change in Account Payables is $3.1 million, which was up 236.68% from $916,000 recorded in FY2023.
  • In the past 5 years, Pacira BioSciences' Change in Account Payables ranged from a high of $6.3 million in FY2022 and a low of -$10.3 million during FY2021.
  • Its 3-year average for Change in Account Payables is $3.4 million, with a median of $3.1 million in 2024.
  • As far as peak fluctuations go, Pacira BioSciences' Change in Account Payables crashed by 209.84% in 2021, and later skyrocketed by 236.68% in 2024.
  • Yearly analysis of 5 years shows Pacira BioSciences' Change in Account Payables stood at -$3.3 million in 2020, then slumped by 209.84% to -$10.3 million in 2021, then skyrocketed by 161.12% to $6.3 million in 2022, then tumbled by 85.40% to $916,000 in 2023, then spiked by 236.68% to $3.1 million in 2024.